Non-genomic cell growth inhibition by progesterone. Cell cycle retardation and induction of cell death

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 3749-3755

  Bertelsen, Eirin Listau ^a   Endresen, Petter Cappelen ^b   Ørbo, Anne ^a   Sager, Georg ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Cell cycle; Non genomic cell growth inhibition; Progesterone

Indexed keywords

PROGESTERONE; PROGESTERONE RECEPTOR; GROWTH INHIBITOR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL POPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; EXPOSURE; FEMALE; FETAL CALF SERUM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MONOLAYER CULTURE; MORPHOMETRICS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; BIOSYNTHESIS; CELL GROWTH; DRUG EFFECT; METABOLISM; PATHOLOGY; UTERINE CERVIX TUMOR;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL GROWTH PROCESSES; FEMALE; GROWTH INHIBITORS; HUMANS; PROGESTERONE; RECEPTORS, PROGESTERONE; UTERINE CERVICAL NEOPLASMS;

EID: 14944383268     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Clarke CL and Sutherland RL: Progestin regulation of cellular proliferation. Endocr Rev 11: 266-301, 1990.
2. Horwitz KB: The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13: 146-163, 1992.
3. Graham JD and Clarke CL: Physiological action of progesterone in target tissues. Endocr Rev 18: 502-519, 1997.
4. Sutherland RL, Prall OWJ, Watts CKW and Musgrove EA: Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 3: 63-72, 1998.
5. Horwitz KB, Wei LL, Sedlacek SM and d'Arville CN: Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res 41: 249-316, 1985.
6. Beato M, Chavez S and Truss M: Transcriptional regulation by steroid hormones. Steroids 61: 240-251, 1996.
7. Beato M: Gene regulation by steroid hormones. Cell 56: 335-344, 1989.
8. Lin VC, Ng EH, Aw SE, Tan MG, Ng EH, Chan VS and Ho GH: Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 5: 395-403, 1999.
9. Lange CA, Richer JK and Horwitz KB: Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13: 829-836, 1999.
10. Lange CA: Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol Endocrinol 18: 269-278, 2004.
11. Baldi E, Luconi M, Bonaccorsi L and Forti G: Nongenomic effects of progesterone on spermatozoa: mechanisms of signal transduction and clinical implications. Front Biosci 3: D1051-D1059, 1998.
12. Revelli A, Massobrio M and Tesarik J: Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev 19: 3-17, 1998.
13. Schmidt BM, Gerdes D, Feuring M, Falkenstein E, Christ M and Wehling M: Rapid, nongenomic steroid actions: A new age? Front Neuroendocrinol 21: 57-94, 2000.
14. Simoncini T and Genazzani AR: Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148: 281-292, 2003.
15. Brann DW, Hendry LB and Mahesh VB: Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol 52: 113-133, 1995.
16. Ørbo A, Jaeger R, Kjørstad KE and Sager G: Progesterone and beta-estradiol influence the cell density-dependent distribution of cyclic nucleotides across the cell membrane of human C4-I cells (squamous carcinoma of the uterine cervix) by a non-genomic mechanism. Anticancer Res 15: 1905-1909, 1995.
17. Sager G, Ørbo A, Jaeger R and Engstrom C: Non-genomic effects of progestins-inhibition of cell growth and increased intracellular levels of cyclic nucleotides. J Steroid Biochem Mol Biol 84: 1-8, 2003.
18. Ørbo A, Jaeger R and Sager G: Serum modifies the concentration-dependent effects that sex steroids exert on cGMP and cAMP levels, and the growth of human C4-I cells (carcinoma of the uterine cervix). Int J Oncol 5: 619-625, 1994.
19. Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ and Zheng W: Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol 79: 169-176, 2000.
20. Yu S, Lee M, Shin S and Park J: Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. J Cell Biochem 82: 445-451, 2001.
21. Auersperg N and Hawryluk AP: Chromosome observations on three epithelial-cell cultures derived from carcinomas of the human cervix. J Natl Cancer Inst 28: 605-627, 1962.
22. Berthois Y, Katzenellenbogen JA and Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496-2500, 1986.
23. Brons PP, Van Erp PE and Pennings AH: Simultaneous DNA content and cell-surface immunofluorescence analysis. Methods Cell Biol 41: 95-102, 1994.
24. Chou TC: Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 39: 253-276, 1976.
25. Blondeau JP and Baulieu EE: Progesterone receptor characterized by photoaffinity labelling in the plasma membrane of Xenopus laevis oocytes. Biochem J 219: 785-792, 1984.
26. 2+ in vascular smooth muscle cells. Circ Res 76: 973-979, 1995.
27. Blackmore PF, Beebe SJ, Danforth DR and Alexander N: Progesterone and 17 alpha-hydroxyprogesterone - novel stimulators of calcium influx in human sperm. J Biol Chem 265: 1376-1380, 1990.
28. Blackmore PF, Neulen J, Lattanzio F and Beebe SJ: Cell surface-binding sites for progesterone mediate calcium uptake in human sperm. J Biol Chem 266: 18655-18659, 1991.
29. Meizel S and Turner KO: Progesterone acts at the plasma membrane of human sperm. Mol Cell Endocrinol 77: R1-R5, 1991.
30. 2+ influx. Biochem J 264: 539-546, 1989.
31. Bonaccorsi L, Krausz C, Pecchioli P, Forti G and Baldi E: Progesterone-stimulated intracellular calcium increase in human spermatozoa is protein kinase C-independent. Mol Hum Reprod 4: 259-268, 1998.
32. O'Toole CM, Roldan ER and Fraser LR: Protein kinase C activation during progesterone-stimulated acrosomal exocytosis in human spermatozoa. Mol Hum Reprod 2: 921-927, 1996.
33. Bonaccorsi L, Luconi M, Forti G and Baldi E: Tyrosine kinase inhibition reduces the plateau phase of the calcium increase in response to progesterone in human sperm. FEBS Lett 364: 83-86, 1995.
34. Luconi M, Bonaccorsi L, Krausz C, Gervasi G, Forti G and Baldi E: Stimulation of protein tyrosine phosphorylation by platelet-activating factor and progesterone in human spermatozoa. Mol Cell Endocrinol 108: 35-42, 1995.
35. Luconi M, Krausz C, Forti G and Baldi E: Extracellular calcium negatively modulates tyrosine phosphorylation and tyrosine kinase activity during capacitation of human spermatozoa. Biol Reprod 55: 207-216, 1996.
36. Tesarik J, Moos J and Mendoza C: Stimulation of protein tyrosine phosphorylation by a progesterone receptor on the cell surface of human sperm. Endocrinology 133: 328-335, 1993.
37. Vankalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J and Giaccone G: Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 67: 284-289, 1993.
38. Yang CP, Cohen D, Greenberger LM, Hsu SI and Horwitz SB: Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem 265: 10282-10288, 1990.
39. Gruol DJ and Bourgeois S: Expression of the mdr1 P-glycoprotein gene: a mechanism of escape from glucocorticoid-induced apoptosis. Biochem Cell Biol 72: 561-571, 1994.
40. Barnes KM, Dickstein B, Cutler GB, Fojo T and Bates SE: Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 35: 4820-4827, 1996.
41. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A and Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun 258: 513-518, 1999.
42. Schultz C, Vaskinn S, Kildalsen H and Sager G: Cyclic AMP stimulates the cyclic GMP egression pump in human erythrocytes: Effects of probenecid, verapamil, progesterone, theophylline, IBMX, forskolin, and cyclic AMP on cyclic GMP uptake and association to inside-out vesicles. Biochemistry 37: 1161-1166, 1998.
43. Ørbo A, Kjørstad KE, Jaeger R and Sager G: Rapid non-genomic and concentration-dependent effects of progesterone in C4-I cells on the proposed tumor marker: ratio between extracellular cGMP and cAMP levels. Int J Oncol 6: 1279-1282, 1995.
44. Flo K, Hansen M, Ørbo A, Kjørstad KE, Maltau JM and Sager G: Effect of probenecid, verapamil and progesterone on the concentration- dependent and temperature-sensitive human erythrocyte uptake and export of guanosine 3′,5′ cyclic monophosphate (cGMP). Scand J Clin Lab Invest 55: 715-721, 1995.
45. Musgrove EA, Lee CS and Sutherland RL: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11: 5032-5043, 1991.
46. Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
47. Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell 65: 1097-1098, 1991.
48. Nakano R: Apoptosis: gene-directed cell death. An overview. Horm Res 48 (Suppl 3): 2-4, 1997.
49. Rose PG: Endometrial carcinoma. N Engl J Med 335: 640-649, 1996.
50. Vereide AB, Arnes M, Straume B, Maltau JM and Ørbo A: Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 91: 526-533, 2003.